CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex ...

Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...

In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...

Among 100 surveyed U.S. patients with HAE, 89% of whom were on long-term prophylaxis therapies and 11% of whom were on on-demand therapies only, 34% reported having at least one attack per month and ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...

The past few years have been challenging for the biotech.